Microbot Medical
MBOT
25 hedge funds and large institutions have $3.6M invested in Microbot Medical in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 5 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0.54% less ownership
Funds ownership: 10.43% → 9.88% (-0.54%)
7% less funds holding
Funds holding: 27 → 25 (-2)
22% less capital invested
Capital invested by funds: $4.65M → $3.6M (-$1.04M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$24.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.88K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.31K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.5K |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$93K |
| 2 |
Millennium Management
New York
|
-$88K |
| 3 |
BAM
Blueshift Asset Management
Red Bank,
New Jersey
|
-$81K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$21.9K |
| 5 |
BlackRock
New York
|
-$14.5K |
MBOT Hedge Fund Activity: Q2 2022 in Review
25 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Microbot Medical (MBOT) for Q2 2022, worth a combined $3.6M — down 22% from $4.65M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MBOT and 3 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $24.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $93K sold.
- 25 institutional investors held Microbot Medical (MBOT) as of Q2 2022, down from 27 in Q1 2022.
- Funds reported $3.6M of Microbot Medical stock for Q2 2022, down 22% quarter-over-quarter.
- 3 funds opened new Microbot Medical positions in Q2 2022 and 5 closed out, a net change of -2 holders.
- The largest Microbot Medical buyer in Q2 2022 was Renaissance Technologies, an estimated $24.5K added.
- The largest Microbot Medical seller in Q2 2022 was Citadel Advisors, an estimated $93K sold.
Based on aggregated 13F filings for Q2 2022.